Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Videos
Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.
Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.
Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Corey S. Cutler, MD, MPH, FRCPC, provides insight on the case of a 49-year-old man with chronic GVHD and reviews current and emerging treatment options for disease management.
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.
Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
